Holen Sie sich die Stockscreener-App
26.74
0.11%
0.03
Handel nachbörslich:
26.69
-0.05
-0.19%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$26.71
Offen:
$26.59
24-Stunden-Volumen:
19.37M
Relative Volume:
0.50
Marktkapitalisierung:
$151.54B
Einnahmen:
$59.37B
Nettoeinkommen (Verlust:
$4.25B
KGV:
14.61
EPS:
1.83
Netto-Cashflow:
$8.23B
1W Leistung:
+1.17%
1M Leistung:
+4.25%
6M Leistung:
-5.71%
1J Leistung:
-5.85%
1-Tages-Spanne:
$26.38
$26.77
1-Wochen-Bereich:
$25.57
$26.77
52-Wochen-Spanne:
$24.48
$31.54
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.74 | 151.54B | 59.37B | 4.25B | 8.23B | 0.74 |
|
LLY
Lilly Eli Co
|
795.67 | 715.56B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
87.37 | 388.07B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
145.85 | 351.15B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
180.00 | 318.09B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
99.45 | 251.57B | 63.17B | 12.15B | 14.84B | 4.77 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Sulfasalazine Market Top Companies StudyPfizer Inc., Teva - openPR
Pfizer (NYSE:PFE) Trading Down 0.2%Here's What Happened - MarketBeat
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction - Benzinga
Burkitt Lymphoma Global Clinical Trials Review 2024: Clinical Trials by Region, Country, Trial Status, Trial Phase, Sponsor Type and End Point Status - GlobeNewswire Inc.
Should Value Investors Buy Pfizer (PFE) Stock? - Yahoo Finance
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Pfizer’s colorectal cancer combo therapy gains accelerated approval from FDA - Yahoo! Voices
FDA approves new use for Pfizer’s Braftovi combo - The Pharma Letter
Neostigmine Methylsulfate Injection Market Key Players - openPR
Phenobarbital Market Key Players AnalysisSanofi, Pfizer - openPR
Pfizer's 2025 'Boring' Outlook Had A Nice Surprise That Was Overlooked - Seeking Alpha
Stuart Therapeutics Announces the Appointment of Two New Board Members - Quantisnow
Why Pfizer Inc. (PFE) Is One of the Best Stocks to Buy and Hold for 3 Years? - Yahoo Finance
Pfizer Just Reassured Investors, but Is the Stock a Buy? - sharewise
Pfizer Inc. (PFE) Is Among the Best Dividend Leaders to Buy According to Wall Street Analysts - Insider Monkey
The three-year loss for Pfizer (NYSE:PFE) shareholders likely driven by its shrinking earnings - Yahoo Finance
Pfizer - Contract Pharma
Market Today: Qualcomm's Legal Victory and Pfizer's FDA Approval Highlight Key Developments - GuruFocus.com
Traders Purchase High Volume of Call Options on Pfizer (NYSE:PFE) - MarketBeat
Pfizer cost cutting leads to Tampa layoffs - The Business Journals
Pfizer gets FDA accelerated approval for Braftovi (PFE:NYSE) - Seeking Alpha
Pfizer Gains FDA Approval for Colorectal-Cancer Treatment - Marketscreener.com
Pfizer to lay off 62 in Tampa - Business Observer
Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer - Business Wire
Pfizer (NYSE:PFE) Stock Price Up 1.6%Time to Buy? - MarketBeat
Is Pfizer (PFE) a Cheap NYSE Stock to Invest in Now? - Insider Monkey
Phenobarbital Market CAGR of 5% Trends and Growth Analysis By 2024 to 2031 | Sanofi, Pfizer Inc., Novartis AG, - EIN News
Pfizer Inc. (NYSE:PFE) Stake Reduced by Principal Financial Group Inc. - MarketBeat
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts - BioSpace
Judge Wrongly Axed $107M IP Verdict, Pfizer Tells Fed. Circ. - Law360
Why Pfizer (PFE) Dipped More Than Broader Market Today - Yahoo Finance
Pfizer Colleagues Celebrate Native American Heritage - Pfizer
Pfizer (NYSE:PFE) Trading Up 0.4%Here's What Happened - MarketBeat
Liposomal Doxorubicin Market to Witness Massive Growth | Major Giants Pfizer, Ipsen, Johnson & Johnson - openPR
Is Pfizer Stock A Buy After Rallying On Its 2025 Guidance? - Investor's Business Daily
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26? - Yahoo Finance
PFIZER INC : Gets a Neutral rating from UBS - Marketscreener.com
Stomach Cancer Drugs Market Future Business Opportunities - openPR
Pfizer's SWOT analysis: stock outlook amid pipeline progress and cost cuts - Investing.com
Pfizer Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Jim Cramer’s Take on Pfizer (PFE): Can CEO Dr. Bourla’s Bold Strategy Overcome Debt and Turn the Stock Around? - Yahoo Finance
Pfizer Momentum Shift Makes Me Less Bullish (Technical Analysis) (NYSE:PFE) - Seeking Alpha
Satellite Images Reveal Russian Military Movements in Syria - Yahoo Finance
Pfizer (NYSE:PFE) Shares Down 0.4% on Analyst Downgrade - MarketBeat
Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call (PFE) - Seeking Alpha
Pfizer eyes 2025 revenue growth despite post-COVID challenges, activist pressure - MM+M Online
Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations - Yahoo Finance
Pfizer reiterated at Market Perform by analyst following FY25 guidance - Investing.com Canada
Truist cuts Pfizer shares target, retains buy rating on growth projections - Investing.com
Pfizer: Jefferies confirms its analysis on the stock - Marketscreener.com
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy - Yahoo! Voices
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.19%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):